CompanyOverview\|NYSE:PFE] A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. (NYSE: PFE) certainly catches the eye of income- ...

The transaction is expected to close in the third quarter subject to fulfillment of customary closing conditions, including receipt of required regulatory approvals and 3SBio shar ...

Enbrel revenues declined 6% to $140 million. Pfizer’s acquisition of Seagen in December 2023 added antibody-drug conjugates or ADCs — Adcetris, Padcev, Tukysa and Tivdak — to its cancer portfolio.

Takeda has announced a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending European Commission (EC) approval of Adcetris (brentuximab vedotin) in combination ...

Takeda has received a new recommendation from the European Medicines Agency’s human medicines committee for its Pfizer-partnered blood cancer drug Adcetris (brentuximab vedotin). The Committee for ...

Takeda UK has announced that the National Institute for Health and Care Excellence (NICE) has recommended Adcetris (brentuximab vedotin) as part of a combination treatment for adults with untreated ...

Pfizer Inc. announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Adcetris (brentuximab vedotin) in combination with ...

Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ineligible for autologous stem cell transplantation. The FDA has approved ...

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green light to treat large B-cell lymphoma (LBCL). The CD30-directed antibody ...

This marks the eighth FDA-approved indication for ADCETRIS, solidifying its role in the treatment of lymphomas. According to InvestingPro analysis, Pfizer's stock is currently trading near its 52 ...

Approval is based on positive data from the Phase 3 ECHELON-3 trial, which demonstrated ADCETRIS regimen reduced the risk of death by 37%, a statistically significant, clinically meaningful ...